Volume 171, Issue 1, (January 2022-1-1), Pages OFC-264
Articles in this issue:
1. Cover 1(with editorial board)
2. Information for readers
3. Contents
4. Information for authors
5. Endocrine surgery: Great accomplishments, future challenges
- Pages 1-5.
- Siperstein, Allan, MD.
- PDF
6. Dr. Janice L. Pasieka receives the Oliver Cope Meritorious Achievement Award of the American Association of Endocrine Surgeons
- Pages 6-7.
- Carty, Sally E., MD.
- PDF
7. Racial disparities in the utilization of parathyroidectomy among patients with primary hyperparathyroidism: Evidence from a nationwide analysis of Medicare claims
- Pages 8-16.
- Alobuia, Wilson M., MD, Meng, Tong, MPP, Cisco, Robin M., MD, Lin, Dana T., MD, Suh, Insoo, MD, Tamura, Manjula Kurella, MD, MPH, Trickey, Amber W., PhD, MS, CPH, Kebebew, Electron, MD, and Seib, Carolyn D., MD, MAS.
- PDF
8. Discussion
9. Is routine 24-hour urine calcium measurement useful during the evaluation of primary hyperparathyroidism?
- Pages 17-22.
- Li, Shimena R., MD, McCoy, Kelly L., MD, Levitt, Helena E., MD, Kelley, Meghan L., BS, Carty, Sally E., MD, and Yip, Linwah, MD.
- PDF
10. Discussion
11. Stones left unturned: Missed opportunities to diagnose primary hyperparathyroidism in patients with nephrolithiasis
- Pages 23-28.
- Lui, Michael S., MD, Fisher, Jason C., MD, Underwood, Hunter J., MD, Patel, Kepal N., MD, and Ogilvie, Jennifer B., MD.
- PDF
12. Discussion
13. Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea
- Pages 29-34.
- Huang, Siu-Yuan, MD, Burchette, Raoul, MS, Chung, Joanie, MPH, and Haigh, Philip I., MD, MSc, FACS, FRCSC.
- PDF
14. Discussion
15. How and when is multiglandular disease diagnosed in sporadic primary hyperparathyroidism?
- Pages 35-39.
- Shah, Ujas S., MD, McCoy, Kelly L., MD, Kelley, Meghan L., BS, Carty, Sally E., MD, and Yip, Linwah, MD.
- PDF
16. Recurrence after successful parathyroidectomy—Who should we worry about?
- Pages 40-46.
- Shirali, Aditya S., MD, Wu, Si-Yuan, MD, Chiang, Yi-Ju, MSPH, Graham, Paul H., MD, Grubbs, Elizabeth G., MD, Lee, Jeffrey E., MD, Perrier, Nancy D., MD, and Fisher, Sarah B., MD.
- PDF
17. Discussion
18. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism
- Pages 47-54.
- Graves, Claire E., MD, Hope, Thomas A., MD, Kim, Jina, MD, Pampaloni, Miguel H., MD, PhD, Kluijfhout, Wouter, MD, PhD, Seib, Carolyn D., MD, MAS, Gosnell, Jessica E., MD, Shen, Wen T., MD, Roman, Sanziana A., MD, Sosa, Julie A., MD, MA, Duh, Quan-Yang, MD, and Suh, Insoo, MD.
- PDF
19. Discussion
20. A cost-utility analysis of 18F-fluorocholine–positron emission tomography imaging for localizing primary hyperparathyroidism in the United States
- Pages 55-62.
- Yap, Ava, MD, MHS, Hope, Thomas A., MD, Graves, Claire E., MD, Kluijfhout, Wouter, MD, Shen, Wen T., MD, MA, Gosnell, Jessica E., MD, Sosa, Julie A., MD, MA, Roman, Sanziana A., MD, Duh, Quan-Yang, MD, and Suh, Insoo, MD.
- PDF
21. Discussion
22. Data to inform counseling on parathyroidectomy for secondary hyperparathyroidism of renal origin
- Pages 63-68.
- Williams-Karnesky, Rebecca L., MD, PhD, MEdPsych, Krumeich, Lauren, MD, MS, Wachtel, Heather, MD, Fraker, Douglas L., MD, Wirtalla, Chris, BA, Venuto, Frank Anthony, CRNP, Sellers, Pamela, RN, and Kelz, Rachel R., MD, MSCE, MBA.
- PDF
23. Discussion
24. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients
- Pages 69-76.
- Sutton, Whitney, MD, Chen, Xiaomeng, MSPH, Patel, Palak, BS, Karzai, Shkala, MD, Prescott, Jason D., MD, PhD, Segev, Dorry L., MD, PhD, McAdams-DeMarco, Mara, PhD, and Mathur, Aarti, MD.
- PDF
25. Discussion
26. Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes
- Pages 77-87.
- Shariq, Omair A., MBBS, MSc, Lines, Kate E., PhD, English, Katherine A., MBBS, MMedStat, Jafar-Mohammadi, Bahram, MBBCh, DPhil, Prentice, Philippa, MBBChir, PhD, Casey, Ruth, MBBCh, PhD, Challis, Benjamin G., MBBChir, PhD, Selberherr, Andreas, MD, PhD, Boon, Hannah, BSc, MSc, Cranston, Treena, BSc, DipRCPath, Ryan, Fiona J., MBBCh, MD, Mihai, Radu, MD, PhD, Healy, Ultan, MBBCh, Kurzawinski, Tom, PhD, FRCS, Dattani, Mehul T., MD, FRCP, Bancos, Irina, MD, Dy, Benzon M., MD, Lyden, Melanie L., MD, MHPE, Young, William F., MD, MSc, McKenzie, Travis J., MD, Richards, Duncan, MA, DM, and Thakker, Rajesh V., MD, FRS.
- PDF
27. Discussion
28. A prospective study of carcinoid crisis with no perioperative octreotide
- Pages 88-93.
- Wonn, Sarah M., MD, Ratzlaff, Anna N., BS, Pommier, SuEllen J., PhD, McCully, Belinda H., PhD, and Pommier, Rodney F., MD.
- PDF
29. Discussion
30. Shinrin-yoku, yoga and other strategies in the fight against COVID-19
- Pages 94-95.
- Pasieka, Janice L., MD, FRCSC, FACS.
- PDF
31. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving
- Pages 96-103.
- Chomsky-Higgins Menut, Kathryn, MD, MS, Pearlstein, Sarah Sims, MD, Conroy, Patricia C., MD, Roman, Sanziana A., MD, Shen, Wen T., MD, MA, Gosnell, Jessica, MD, Sosa, Julie Ann, MD, MA, Duh, Quan-Yang, MD, and Suh, Insoo, MD.
- PDF
32. Discussion
33. Computed tomography (CT) scan identified necrosis, but is it a reliable single parameter for discerning between malignant and benign adrenocortical tumors?
- Pages 104-110.
- Garay-Lechuga, Daniel, MD, Pérez-Soto, Rafael Humberto, MD, Hernández-Acevedo, Juan David, MD, Butrón-Hernández, David, MD, Sierra-Salazar, Mauricio, MD, Pantoja-Millán, Juan Pablo, MD, Herrera, Miguel F., PhD, and Velázquez-Fernández, David, MSc, PhD.
- PDF
34. Discussion
35. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment
- Pages 111-118.
- Baechle, Jordan J., MD, Hanna, David N., MD, Sekhar, Konjeti R., PhD, Rathmell, Jeffrey C., PhD, Rathmell, Wendy Kimryn, MD, PhD, and Baregamian, Naira, MD, MMS, FACS.
- PDF
36. Discussion
37. Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics
- Pages 119-129.
- Subramanian, Chitra, PhD, MBA, and Cohen, Mark S., MD, FACS, FSSO.
- PDF
38. Discussion
39. Thyroid surgery: surgical health equity, best practices in surgical education, and leveraging the power of collaboration
- Pages 130-131.
- Kelz, Rachel R., MD, MSCE, MBA.
- PDF
40. Association of the Affordable Care Act with access to highest-volume centers for patients with thyroid cancer
- Pages 132-139.
- Greenberg, Jacques A., MD, Thiesmeyer, Jessica W., Ullmann, Timothy M., MD, Egan, Caitlin E., MD, Valle Reyes, Fernando, MD, Moore, Maureen D., MD, Ivanov, Nikolay A., BS, Laird, Amanda M., MD, Finnerty, Brendan M., MD, Zarnegar, Rasa, MD, Fahey, Thomas J., MD, and Beninato, Toni, MD, MS.
- PDF
41. Discussion
42. Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma
- Pages 140-146.
- Thiesmeyer, Jessica W., MD, Limberg, Jessica, MD, Ullmann, Timothy M., MD, Greenberg, Jacques A., MD, Egan, Caitlin E., MD, Moore, Maureen, MD, Finnerty, Brendan M., MD, Laird, Amanda M., MD, Zarnegar, Rasa, MD, Fahey, Thomas J., MD, and Beninato, Toni, MD, MS.
- PDF
43. Discussion
44. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules
- Pages 147-154.
- Hu, Q. Lina, MD, MS, Schumm, Max A., MD, Zanocco, Kyle A., MD, MS, Yeh, Michael W., MD, Livhits, Masha J., MD, and Wu, James X., MD.
- PDF
45. Discussion
46. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier–suspicious results
- Pages 155-159.
- Babazadeh, Nasim T., MD, Sinclair, Tiffany J., MD, Krishnamurthy, Vikram, MD, Jin, Judy, MD, Heiden, Katherine B., MD, Shin, Joyce, MD, Berber, Eren, MD, and Siperstein, Allan, MD.
- PDF
47. Implications of radiofrequency ablation in patients undergoing thyroid surgery for benign disease in the United States
- Pages 160-164.
- Kim, Jina, MD, Sun, Zhifei, MD, Cummins, Marcus, BS, Donohue, Kevin C., BS, Lea, Robin, BS, Graves, Claire E., MD, Shen, Wen T., MD, Gosnell, Jessica E., MD, Roman, Sanziana A., MD, Sosa, Julie A., MD, MA, Duh, Quan-Yang, MD, and Suh, Insoo, MD.
- PDF
48. Discussion
49. Intraoperative trans-laryngeal ultrasound (LUSG) of the vocal cord is a novel method of confirming the recurrent laryngeal nerve (RLN) integrity during thyroid and neck surgery
- Pages 165-171.
- Fung, Matrix Man Him, FRCS, and Lang, Brian Hung-Hin, MS, FRACS.
- PDF
50. Discussion
51. Optimal surgeon-volume threshold for neck dissections in the setting of primary thyroid malignancies
- Pages 172-176.
- Sharma, Rahul K., MD, Lee, Jihui, PhD, Liou, Rachel, MD, McManus, Catherine, MD, MS, Lee, James A., MD, and Kuo, Jennifer H., MD, MS.
- PDF
52. Discussion
53. Medullary thyroid cancer: What is the optimal management of the lateral neck in a node negative patient at index operation?
- Pages 177-181.
- Szabo Yamashita, Thomas, MD, Rogers, Richard T., MD, Foster, Trenton R., MD, Lyden, Melanie L., MD, Morris, John C., MD, Thompson, Geoffrey B., MD, McKenzie, Travis, MD, and Dy, Benzon M., MD.
- PDF
54. Discussion
55. A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma
- Pages 182-189.
- Ahn, Jong-hyuk, MD, Kwak, Jung Hak, MD, Yoon, Sang Gab, MD, Yi, Jin Wook, MD, Yu, Hyeong Won, MD, PhD, Kwon, Hyungju, MD, PhD, Kim, Su-jin, MD, PhD, and Lee, Kyu Eun, MD, PhD.
- PDF
56. Discussion
57. Thyroid lobectomy as a cost-effective approach in low-risk papillary thyroid cancer versus active surveillance
- Pages 190-196.
- Youssef, Mohanad R., MD, Attia, Abdallah S., MD, Omar, Mahmoud, MD, Aboueisha, Mohamed, MD, Freeman, Meredith N., MSc, Shama, Mohamed, MD, MSc, MRCS, EBSQ, and Kandil, Emad, MD, MBA, FACE, FACS.
- PDF
58. Discussion
59. Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer
- Pages 197-202.
- MacKinney, Erin C., MD, Kuchta, Kristine M., MS, Winchester, David J., MD, Khokar, Amna M., MD, Holoubek, Simon A., DO, Moo-Young, Tricia A., MD, and Prinz, Richard A., MD.
- PDF
60. Discussion
61. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm
- Pages 203-211.
- Holoubek, Simon A., DO, MPH, MacKinney, Erin C., MD, Khokar, Amna M., MD, Kuchta, Kristine M., MS, Winchester, David J., MD, Prinz, Richard A., MD, and Moo-Young, Tricia A., MD.
- PDF
62. Discussion
63. Ambient particulate matter air pollution is associated with increased risk of papillary thyroid cancer
- Pages 212-219.
- Karzai, Shkala, MD, Zhang, Zhenyu, PhD, Sutton, Whitney, MD, Prescott, Jason, MD, PhD, Segev, Dorry L., MD, PhD, McAdams-DeMarco, Mara, PhD, Biswal, Shyam S., PhD, Ramanathan, Murugappan, MD, and Mathur, Aarti, MD, PhD.
- PDF
64. Discussion
65. Avoiding delays in time to renal transplantation: Pretransplant thyroid malignancy does not affect patient or graft survival after renal transplantation
- Pages 220-226.
- Delman, Aaron M., MD, Turner, Kevin M., MD, Ammann, Allison M., MD, Tang, Alice, MD, Steward, David, MD, and Holm, Tammy M., MD, PhD, FACS.
- PDF
66. Discussion
67. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer
- Pages 227-234.
- Zhao, Bixiao, MD, PhD, Aggarwal, Abha, PhD, Marshall, Jessica A., BSc, Barletta, Justine A., MD, Kijewski, Marie F., ScD, Lorch, Jochen H., MD, MS, and Nehs, Matthew A., MD.
- PDF
68. Discussion
69. Inhibition of autophagy mitigates cell migration and invasion in thyroid cancer
- Pages 235-244.
- Holm, Tammy M., MD, PhD, FACS, Bian, Z. Christine, MS, Manupati, Kanakaraju, PhD, and Guan, Jun-Lin, PhD.
- PDF
70. Discussion
71. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer
- Pages 245-251. Beck, Anna C., MD, Rajan, Anand, MBBS, Landers, Shannon, Kelley, Sarah, Bellizzi, Andrew M., MD, Lal, Geeta, MD, MSc, Sugg, Sonia L., MD, Howe, James R., MD, Chan, Carlos H., MD, PhD, and Weigel, Ronald J., MD, PhD.
- PDF
72. Discussion
73. The glass podium: Gender representation within the American Association of Endocrine Surgeons (AAES) from 2010 to 2019
- Pages 252-258.
- Wrenn, Sean M., MD, Gartland, Rajshri M., MD, MPH, Kuo, Lindsay E., MD, MBA, and Cho, Nancy L., MD.
- PDF
74. Discussion
75. Perspectives on virtual interviews—A follow-up study of the Comprehensive Endocrine Surgery Fellowship interview process
- Pages 259-264.
- Geary, Alaina D., MD, MSHPE, Wang, Tracy S., MD, MPH, Lindeman, Brenessa, MD, MEHP, Kuo, Jennifer H., MD, Lyden, Melanie L., MD, Shen, Wen T., MD, MA, Morris-Wiseman, Lilah F., MD, Carty, Sally E., MD, and Drake, Frederick Thurston, MD, MPH.
- PDF
76. Discussion